Delivery of G3139 using releasable PEG-linkers: Impact on pharmacokinetic profile and anti-tumor efficacy

Journal of Controlled Release

Volumn 119, Issue 2, 2007, Pages 143-152

  Zhao, Hong ^a   Peng, Ping ^a   Longley, Clifford ^a   Zhang, Yue ^a   Borowski, Virna ^a   Mehlig, Mary ^a   Reddy, Prasanna ^a   Xia, Jing ^a   Borchard, Gerrit ^a   Lipman, Jack ^a   Benimetskaya, Luba ^b   Stein, C A ^b  

^a Enzon Pharmaceuticals   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

518A2 melanoma; G3139; Immunostimulation; PEG (polyethylene glycol); Pharmacokinetics

Indexed keywords

IMMUNOSTIMULATION; MELANOMA CELLS; MITOCHONDRIA; RELEASABLE LINKERS;

ENZYME ACTIVITY; IMMUNOLOGY; OLIGONUCLEOTIDES; PHARMACOKINETICS; POLYETHYLENE GLYCOLS; PROTEINS;

DRUG DELIVERY;

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCL 2 ANTISENSE OLIGONUCLEOTIDE; FIBROBLAST GROWTH FACTOR; G 4126; G 4232; HEPARIN BINDING PROTEIN; MACROGOL; OBLIMERSEN; PEGOBLIMERSEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CELL CULTURE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPLEEN CELL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, NUDE; MITOCHONDRIA; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; THIONUCLEOTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248584427     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.12.021     Document Type: Article

References (44)

1. Stein C., Benimetskaya L., and Mani S. Antisense strategies for oncogene inactivation. Semin. Oncol. 32 (2005) 563-572
2. Klasa R., Gillum A., Klem R., and Frankel S. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12 (2002) 193-213
3. Klasa R., Bally M., Ng R., Goldie J., Gascoyne R., and Wong F. Eradication of human non-Hodgkin's lymphoma in SCID mice by Bcl-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin. Cancer Res. 6 (2000) 2492-2500
4. Loomis R., Carbone R., Reiss M., and Lacy J. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab. Clin. Cancer Res. 9 (2003) 1931-1939
5. Cotter F., Waters J., and Cunningham D. Human bcl-2 antisense therapy for lymphomas. Biochim. Biophys. Acta 1489 (1999) 97-106
6. Reed J.C. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol./Oncol. Clin. North Am. 9 (1995) 451-473
7. Miyashita T., and Reed R.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81 (1993) 151-157
8. Kamesaki S., Kamesaki H., Jorgensen T., Tanizawa A., Pommier Y., and Cossman J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 53 (1993) 4251-4256
9. Eder P., DeVine R., Dagle J., and Walder J. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res. Dev. 1 (1991) 141-151
10. Raynaud F., Orr R., Goddard P., Lacey H., Lancashire H., Judson I., Beck T., Bryan B., and Cotter F. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J. Pharmacol. Exp. Ther. 281 (1997) 420-427
11. Lopes de Menezes D., and Mayer L. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother. Pharmacol. 49 (2002) 57-68
12. Wang L., Prakash R., Stein C., Koehn R., and Ruffner D. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Antisense Nucleic Acid Drug Dev. 13 (2003) 169-189
13. Krieg A. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim. Biophys. Acta 1489 (1999) 107-116
14. Krug A., Rothenfusser S., Hornung V., Jahrsdorfer B., Blackwell S., Ballas Z., Endres S., Krieg A., and Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-a/b in plasmacytoid dendritic cells. Eur. J. Immunol. 31 (2001) 2154-2163
15. Agrawal S., and Kandimalla E. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 8 (2002) 114-121
16. Fearon K., Marshall J., Abbate C., Subramanian S., Yee P., Gregorio J., Teshima G., Ott G., Tuck S., van Nest G., and Coffman R. A minimal human immunostimulatory CpG motif that potently induces IFN-g and IFN-a production. Eur. J. Immunol. 33 (2003) 2114-2122
17. Gekeler V., Gimmnich P., Hofmann H.-P., Grebe C., Rommele M., Leja A., Baudler M., Benimetskaya L., Gonser B., Pieles U., Maier T., Wagner T., Sanders K., Beck J.F., Hanauer G., and Stein C.A. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 16 (2006) 83-93
18. Bonora M., Ivanova E., Zarytova V., Burchovich B., and Veronese F. Synthesis and characterization of high molecular mass poly(ethylene glycol)-conjugated oligonucleotides. Bioconjug. Chem. 8 (1997) 793-797
19. Burchovich B., Veronese F., Zarytova V., and Bonora G. Branched poly(ethylene glycol) (bPEG) conjugated antisense oligonucleotides. Nucleosides Nucleotides 17 (1998) 1567-1570
20. Chirila T., Rakoczy P., Garrett K., Xia L., and Constable I. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 23 (2002) 321-342
21. Bonora G. Polymer-conjugated bioactive oligonucleotides. J. Bioact. Compat. Polym. 17 (2002) 375-389
22. Jaschke A., Furste J., Nordhoff E., Millenkamp F., Cech D., and Erdman V. Synthesis and properties of oligodeoxynucleotide-poly(ethylene glycol) conjugates. Nucleic Acids Res. 22 (1994) 4810-4817
23. Rapozzi V., Cogoi S., Spessotto P., Risso A., Bonora G., Quadrifoglio F., and Xodo L. Antigene effect in K562 cells of a PEG-conjugate triplex-forming oligonucleotide targeted to the bcl/abl oncogene. Biochemistry 41 (2002) 502-510
24. Zhao H., Greenwald R., Reddy P., Xia J., and Peng P. A new platform for oligonucleotide delivery utilizing the PEG prodrug approach. Bioconjug. Chem. 40 (2005) 798-804
25. Greenwald R., Choe Y., McGuire J., and C.C. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55 (2003) 217-250
26. Torchilin V. Lipid core micelles for targeted drug delivery. Curr. Drug Deliv. 2 (2005) 319-327
27. Lukyanov A., and Torchilin V. Micelles from lipid derivatives of water soluble polymers as delivery systems for poorly soluble drugs. Adv. Drug Del. Rev. 56 (2004) 1273-1289
28. Greenwald R., Pendri A., Conover C., Zhao H., Choe Y., Martinez A., Shum K., and Guan S. Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine containing compounds. J. Med. Chem. 42 (1999) 3657-3667
29. Guvakova M., Yakubov L., Vlodavsky I., Tonkinson J., and Stein C.A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270 (1995) 2620-2627
30. Benimetskaya L., Miller P., Benimetsky S., Maciaszek A., Guga P., Beaucage S.L., Wilk A., Grajkowski A., Halperin A.L., and Stein C.A. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mol. Pharmacol. 60 (2001) 1296-1307
31. Lai J., Tan W., Benimetskaya L., Miller P., Colombini M., and Stein C.A. A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7494-7499
32. Liu X., Kim C., Yang J., and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1996) 147-157
33. Lai J., Benimetskaya L., Khvorova A., Wu S., Hua E., and Stein C.A. Phoshorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells. Mol. Cancer Ther. 4 (2005) 305-315
34. Patinkin D., Hidmi A., Weiss L., Slavin S., and Katzhendler J. The effect of pegylated antisense acetylcholinesterase on hematopoiesis. Oligonucleotides 13 (2003) 207-216
35. Meyer O., Kirpotin D., Hong K., Sternberg B., Park J., Woodle M., and Papahadjopoulos D. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J. Biol. Chem. 273 (1998) 15621-15627
36. Watson S., Chang Y., O'Connell D., Weigand L., Ringquist S., and Parma D. Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev. 10 (2000) 63-75
37. Springate C., Jackson J., Gleave M., and Burt H. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel in prostate cancer xenograft models. Cancer Chemother. Pharmacol. 56 (2005) 239-247
38. Pun S., Tack F., Bellocq N., Cheng J., Grubbs B., Jensen G., Davis M., Brewster M., Janicot M., Janssens B., Floren W., and Bakker A. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferring-modified, cyclodextrin-based particles. Cancer Biol. Ther. 3 (2004) 641-650
39. Leamon C., Cooper S., and Hardee G. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug. Chem. 14 (2003) 738-747
40. Brus C., Petersen H., Aigner A., Czybayko F., and Kissel T. Physicochemical and biological characterization of polyethylemimine-graft-poly (ethylene glycol) block copolymers as a delivery system for oligonucleotides and ribozymes. Bioconjug. Chem. 15 (2004) 677-684
41. Murthy N., Campbell J., Fausto N., Hoffman AS., and Stayton P. Design and synthesis of pH-responsive polymeric carriers that target uptake and enhance the intracellular delivery of oligonucleotides. J. Control. Release 89 (2003) 365-374
42. Jeong J., Kim S., and Park T. A new antisense oligonucleotide delivery system based on self-assembled ODN-PEG hybrid conjugate micelles. J. Control. Release 93 (2003) 183-191
43. Healy J., Lewis S., Kurz M., Boomer R., Thompson K., Wilson C., and McCauley T. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. 21 (2004) 2234-2246
44. Tonkinson J., and Stein C.A. Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res. 22 (1994) 4268-4275